Philip James Wealth Management Reduces Organon & Co. Stock Position

Investment firm cuts stake in pharmaceutical company by nearly 50%

Apr. 4, 2026 at 10:13am

Got story updates? Submit your updates here. ›

Philip James Wealth Management LLC has reduced its position in Organon & Co. (NYSE: OGN) by 48.4% in the fourth quarter, according to a recent SEC filing. The investment firm previously owned 229,230 shares of the pharmaceutical company's stock, valued at $1.64 million, but sold 214,942 shares during the period.

Why it matters

This move by a major institutional investor signals potential concerns about Organon & Co.'s performance or outlook. As a spin-off from Merck, Organon is focused on women's health, biosimilars, and established pharmaceutical brands, but has faced challenges in a competitive market.

The details

According to the SEC filing, Philip James Wealth Management LLC now owns approximately 0.09% of Organon & Co.'s outstanding shares. The firm cited unspecified reasons for reducing its position in the company. Organon & Co. has a market capitalization of $1.65 billion and its stock is trading around $6.35 per share, down from a 52-week high of $14.70.

  • The position reduction occurred in the fourth quarter of 2025.

The players

Philip James Wealth Management LLC

An investment management firm that has reduced its stake in Organon & Co.

Organon & Co.

A pharmaceutical company focused on women's health, biosimilars, and established brands that was spun off from Merck in 2021.

Got photos? Submit your photos here. ›

The takeaway

This reduction in a major institutional investor's position in Organon & Co. raises questions about the company's long-term prospects and performance in a competitive pharmaceutical market. It will be important to monitor Organon's financial results and strategic direction going forward.